参考文献/References:
[1].Thygesen K,Alpert JS,Jaffe AS,et al. Fourth universal definition of myocardial infarction(2018)[J]. Eur Heart J,2019,40(3):237-269.
[2].中国心血管健康与疾病报告编写组,胡盛寿. 中国心血管健康与疾病报告2020概要[J]. 中国循环杂志,2021,36(6):521-545.
[3].Divakaran S,Singh A,Biery D,et al. Diabetes is associated with worse long-term outcomes in young adults after myocardial infarction:the partners YOUNG-MI registry[J]. Diabetes Care,2020,43(8):1843-1850.
[4].Forcadell MJ,Vila-Córcoles A,de Diego C,et al. Incidence and mortality of myocardial infarction among Catalonian older adults with and without underlying risk conditions:the CAPAMIS study[J]. Eur J Prev Cardiol,2018,25(17):1822-1830.
[5].Cosentino F,Grant PJ,Aboyans V,et al. 2019 ESC Guidelines on diabetes,pre-diabetes,and cardiovascular diseases developed in collaboration with the EASD[J]. Eur Heart J,2020,41(2):255-323.
[6].白颖,丛佳林,程淑莉,等. 急性心肌梗死患者中糖尿病人群的临床特点及随访研究[J]. 中华流行病学杂志,2019,40(6):692-696.
[7].McMurray JJV,Solomon SD,Inzucchi SE,et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med,2019,381(21):1995-2008.
[8].McDonagh TA,Metra M,Adamo M,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J,2021,42(36):3599-3726.
[9].Zinman B,Wanner C,Lachin JM,et al. Empagliflozin,cardiovascular outcomes,and mortality in type 2 diabetes[J]. N Engl J Med,2015,373(22):2117-2128.
[10].Neal B,Perkovic V,Mahaffey KW,et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med,2017,377(7):644-657.
[11].Wiviott SD,Raz I,Bonaca MP,et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2019,380(4):347-357.
[12].Bromage DI,Godec TR,Pujades-Rodriguez M,et al. Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes:a cohort study[J]. Cardiovasc Diabetol,2019,18(1):168.
[13].Kosiborod M,Lam CSP,Kohsaka S,et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs:the CVD-REAL 2 study[J]. J Am Coll Cardiol,2018,71(23):2628-2639.
[14].中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J]. 中华心血管病杂志,2019,47(10):766-783.
[15].Wong CKH,Tang EHM,Man KKC,et al. SGLT2i as fourth-line therapy and risk of mortality,end-stage renal diseases and cardiovascular diseases in patients with type 2 diabetes mellitus[J]. Diabetes Metab,2021,47(4):101196.
[16].Hayashi T,Fukui T,Nakanishi N,et al. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes:comparison with sitagliptin[J]. Cardiovasc Diabetol,2017,16(1):8.
[17].Matsubayashi Y,Yoshida A,Suganami H,et al. Association of increased hepatic insulin clearance and change in serum triglycerides or β-hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin[J]. Diabetes Obes Metab,2020,22(6):947-956.
[18].Paolisso P,Bergamaschi L,Santulli G,et al. Infarct size,inflammatory burden,and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors:a multicenter international registry[J]. Cardiovasc Diabetol,2022,21(1):77.
[19].Cheng L,Fu Q,Zhou L,et al. Effect of SGLT-2 inhibitor,empagliflozin,on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms[J]. Sci Rep,2022,12(1):3525.
[20].Zhang W,Zhang S,Deng Y,et al. Trial of intensive blood-pressure control in older patients with hypertension[J]. N Eng J Med,2021,385(14):1268-1279.
[21].胡晓姣,崔琦,张帅,等. 卡格列净对老年2型糖尿病合并心力衰竭患者血糖及心功能影响[J]. 中国处方药 ,2021,19(11):126-128.
[22].Nunoi K,Sato Y,Kaku K,et al. Renal effects of a sodium-glucose cotransporter 2 inhibitor,tofogliflozin,in relation to sodium intake and glycaemic status[J]. Diabetes Obes Metab,2019,21(7):1715-1724.
[23].李鹏飞,冷飞. 达格列净治疗急性心肌梗死合并应激性高血糖的效果[J]. 中国当代医药,2020,27(20):65-68.
[24].Langslet G,Zinman B,Wanner C,et al. Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME?[J]. Diab Vasc Dis Res,2020,17(6) :1479164120975256.
[25].张廷川,边长勇,李海涛. 早期应用卡格列净对急性心肌梗死合并2型糖尿病患者经皮冠状动脉介入术后心功能及预后的影响[J]. 中国心血管病研究,2022,20(2):166-170.
[26].曹晋,邵英,宋菲菲,等. 达格列净治疗2型糖尿病合并冠心病临床观察[J]. 中国药物与临床,2021,21(14):2526-2528.
[27].Vaduganathan M,Sattar N,Xu J,et al. Stress cardiac biomarkers,cardiovascular and renal outcomes,and response to canagliflozin[J]. J Am Coll Cardiol,2022,79(5):432-444.
[28].辛丽. 达格列净治疗2型糖尿病并冠心病患者的临床效果及对患者凝血功能的影响[J]. 中国当代医药,2022,29(4):93-96.
[29].Xue J,Mraiche F,Zhou D,et al. Elevated myocardial Na+/H+ exchanger isoform 1 activity elicits gene expression that leads to cardiac hypertrophy [J]. Physiol Genomics,2010,42(3):374-383.
[30].Ma J,Chen Z,Ma Y,et al. MicroRNA-19a attenuates hypoxia-induced cardiomyocyte apoptosis by downregulating NHE-1 expression and decreasing calcium overload[J]. J Cell Biochem,2020,121(2):1747-1758.
[31].Garcia-Dorado D,Ruiz-Meana M,Inserte J,et al. Calcium-mediated cell death during myocardial reperfusion[J]. Cardiovasc Res ,2012,94(2):168-180.
[32].Baartscheer A,Schumacher CA,Wüst RC,et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na +/H+ exchanger in rats and rabbits[J]. Diabetologia,2017,60(3):568-573.
[33].Xu Z,Zhang M,Li X,et al. Exercise ameliorates atherosclerosis via up-regulating serum β-hydroxybutyrate levels[J]. Int J Mol Sci,2022,23(7):3788.
[34].Ferrannini E,Mark M,Mayoux E. CV protection in the EMPA-REG OUTCOME trial:a "Thrifty Substrate" hypothesis[J]. Diabetes Care,2016,39(7):1108-1114.
[35].董爱巧,张晓亮,林思朴,等. β-羟基丁酸抑制细胞焦亡减轻心肌缺血再灌注损伤[J]. 心脏杂志,2022,34(1):12-17.
[36].Ahmed AS,Mona MM,Abdel-Kareem MA,et al. SGLT2 inhibitor empagliflozin monotherapy alleviates renal oxidative stress in albino Wistar diabetic rats after myocardial infarction induction[J]. Biomed Pharmacother,2021,139:111624.
[37].Herat LY,Magno AL,Rudnicka C,et al. SGLT2 inhibitor-induced sympathoinhibition:a novel mechanism for cardiorenal protection[J]. JACC Basic Transl Sci,2020,5(2):169-179.
[38].Matthews VB,Elliot RH,Rudnicka C,et al. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2[J]. J Hypertens,2017,35(10):2059-2068.
[39].Shimizu W,Kubota Y,Hoshika Y,et al. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus:the EMBODY trial[J]. Cardiovasc Diabetol,2020,19(1):148.
[40].Paolisso P,Foà A,Bergamaschi L,et al. Hyperglycemia,inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCA[J]. Cardiovasc Diabetol,2021,20(1):33.
[41].Olsen MB,Gregersen I,Sandanger ?,et al. Targeting the inflammasome in cardiovascular disease[J]. JACC Basic Transl Sci,2022,7(1):84-98.
[42].Algoet M,Janssens S,Himmelreich U,et al. Myocardial ischemia-reperfusion injury and the influence of inflammation[J]. Trends Cardiovasc Med,2022:S1050-1738(22)00029-9.
[43].Rock KL,Kono H. The inflammatory response to cell death[J]. Annu Rev Pathol,2008,3:99-126.
[44].Huang S,Frangogiannis NG. Anti-inflammatory therapies in myocardial infarction:failures,hopes and challenges[J]. Br J Pharmacol,2018,175(9):1377-1400.
[45].Chen C,Cong BL,Wang M,et al. Neutrophil to lymphocyte ratio as a predictor of myocardial damage and cardiac dysfunction in acute coronary syndrome patients[J]. Integr Med Res,2018,7(2):192-199.
[46].Somaschini A,Cornara S,Demarchi A,et al. Neutrophil to platelet ratio:a novel prognostic biomarker in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary interve ntion[J]. Eur J Prev Cardiol,2020,27(19):2338-2340.
[47].Li W,Liu Q,Tang Y. Platelet to lymphocyte ratio in the prediction of adverse outcomes after acute coronary syndrome:a meta-analysis[J]. Sci Rep,2017,7:40426.
[48].Shetelig C,Limalanathan S,Hoffmann P,et al. Association of IL-8 with infarct size and clinical outcomes in patients with STEMI[J]. J Am Coll Cardiol,2018,72(2):187-198.
[49].T?llefsen IM,Shetelig C,Seljeflot I,et al. High levels of interleukin-6 are associated with final infarct size and adverse clinical events in patients with STEMI[J]. Open Heart ,2021,8(2):e001869.
[50].Broch K,Anstensrud AK,Woxholt S,et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction[J]. J Am Coll Cardiol,2021,77(15):1845-1855.
[51].von K?nel R,Meister-Langraf RE,Fux M,et al. Prospective association between pro-inflammatory state on admission and posttraumatic stress following acute coronary syndrome[J]. Gen Hosp Psychiatry,2022,74:58-64.
[52].la Grotta R,de Candia P,Olivieri F,et al. Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin[J]. Cell Mol Life Sci,2022,79(5):273.
[53].Harrington J,Udell JA,Jones WS,et al. Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial[J]. Am Heart J,2022,253:86-98.
[54].Tripolt NJ,Kolesnik E,Pferschy PN,et al. Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction—The EMMY trial[J]. Am Heart J,2020,221:39-47.
[55].Savarese G,Butler J,Lund LH,et al. Cardiovascular effects of non-insulin glucose-lowering agents:a comprehensive review of trial evidence and potential cardioprotective mechanisms[J]. Cardiovasc Res,2022,118(10):2231-2252.
[56].Kosiborod M,Gause-Nilsson I,Xu J,et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure[J]. J Diabetes Complications,2017,31(7):1215-1221.
[57].Kato ET,Silverman MG,Mosenzon O,et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus[J]. Circulation,2019,139(22):2528-2536.
[58].Bhatt DL,Szarek M,Steg PG,et al. Sotagliflozin in patients with diabetes and recent worsening heart failure[J]. N Engl J Med,2021,384(2):117-128.
相似文献/References:
[1]林远龙,刘现亮.无复流现象:从基础到临床[J].心血管病学进展,2016,(1):53.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.014]
LIN Yuanlong,LIU Xianliang.From Bench to Bed:No-reflow Phenomenon[J].Advances in Cardiovascular Diseases,2016,(11):53.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.014]
[2]赵劲东,综述,董平栓,等.合并多支血管病变的急性ST段抬高型心肌梗死介入术治疗策略的研究进展[J].心血管病学进展,2016,(3):295.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.021]
ZHAO Jindong,DONG Pingshuan.Research Progress of Interventional Therapy in Patients with ST-elevation
Myocardial Infarction and Multivessel Disease[J].Advances in Cardiovascular Diseases,2016,(11):295.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.021]
[3]余正春,综述,马小静,等.急性心肌梗死并发心源性休克的治疗进展[J].心血管病学进展,2016,(4):441.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.029]
YU Zhengchun,MA Xiaojing.Treatment of Cardiogenic Shock Complicating Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2016,(11):441.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.029]
[4]袁帅,毛玉琳,钱志敏,等.经皮冠脉介入术在高龄老年患者治疗中的研究新进展[J].心血管病学进展,2019,(6):864.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.007]
YUAN Shuai,MAO Yulin,QIAN Zhimin,et al.New Progress in Study of PCI in treatment of Elderly Patients[J].Advances in Cardiovascular Diseases,2019,(11):864.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.007]
[5]元洋洋 李波.Selvester QRS评分系统研究进展[J].心血管病学进展,2019,(7):985.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.005]
YUAN YangyangLI Bo.Research Progress of Selvester QRS Scoring System[J].Advances in Cardiovascular Diseases,2019,(11):985.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.005]
[6]翁子骞 于波.血栓抽吸在急性ST段抬高型心肌梗死中的研究进展[J].心血管病学进展,2019,(7):1035.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.018]
WENG ZiqianYU Bo.Thrombus aspiration in acute ST-segment elevation myocardial infarction[J].Advances in Cardiovascular Diseases,2019,(11):1035.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.018]
[7]林莉 韦铁民.急性心肌梗死后心脏破裂[J].心血管病学进展,2019,(7):1039.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.019]
LIN LiWEI Tiemin.Post-infarction Cardiac Rupture[J].Advances in Cardiovascular Diseases,2019,(11):1039.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.019]
[8]杨颜瑜,苏星,谭敏,等.炎症指标与急性心肌梗死研究进展[J].心血管病学进展,2019,(6):947.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.027]
YANG Yanyu,SU Xing,TAN Min,et al.Relationship Between Inflammation Index and Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(11):947.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.027]
[9]崔小豪 杨志明.和肽素在急性心肌梗死中的研究进展[J].心血管病学进展,2019,(5):726.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.016]
CUI Xiaohao,YANG Zhiming.Copeptin in Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(11):726.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.016]
[10]潘甜 马康华.急性心肌梗死经皮冠脉介入术后冠状动脉无复流的预防和治疗进展[J].心血管病学进展,2019,(5):730.[doi:10.16806/j.cnki.issn.1004-3932019.05.017]
PAN Tian,MA Kanghua.Prevention and Treatment of Coronary Artery No-Reflow after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(11):730.[doi:10.16806/j.cnki.issn.1004-3932019.05.017]